These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| California | 94-2424084 | |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
|
400 Kato Terrace
Fremont, CA
|
94539 | |
| (Address of principal executive offices) | (Zip Code) |
| Large accelerated filer | o | Accelerated filer | o |
| Non-accelerated filer | o | Smaller reporting company | þ |
|
(Do not check if a smaller reporting company)
|
|||
| PART I. FINANCIAL INFORMATION | ||||
| ITEM 1. |
Financial Statements (Unaudited)
|
|||
|
Condensed Consolidated Balance Sheets at August 31, 2014 and May 31, 2014
|
3 | |||
|
Condensed Consolidated Statements of Operations for the Three Months Ended August 31, 2014 and 2013
|
4 | |||
|
Condensed Consolidated Statements of Comprehensive Loss for the Three Months Ended August 31, 2014 and 2013
|
5 | |||
|
Condensed Consolidated Statements of Cash Flows for the Three Months Ended August 31, 2014 and 2013
|
6 | |||
|
Notes to Condensed Consolidated Financial Statements
|
7 | |||
| ITEM 2. |
Management's Discussion and Analysis of Financial Condition and Results of Operations
|
15 | ||
| ITEM 3. |
Quantitative and Qualitative Disclosures About Market Risks
|
19 | ||
| ITEM 4. |
Controls and Procedures
|
19 | ||
| PART II. OTHER INFORMATION | ||||
| ITEM 1. |
Legal Proceedings
|
20 | ||
| ITEM 1A. |
Risk Factors
|
20 | ||
| ITEM 2. |
Unregistered Sales of Equity Securities and Use of Proceeds
|
24 | ||
| ITEM 3. |
Defaults Upon Senior Securities
|
24 | ||
| ITEM 4. |
Mine Safety Disclosures
|
24 | ||
| ITEM 5. |
Other Information
|
24 | ||
| ITEM 6. |
Exhibits
|
24 | ||
| SIGNATURE PAGE | 25 | |||
| Index to Exhibits | 26 | |||
|
August 31,
|
May 31,
|
|||||||
|
2014
|
2014
|
|||||||
| (1) | ||||||||
|
ASSETS
|
||||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$ | 2,075 | $ | 1,809 | ||||
|
Accounts receivable, net
|
2,098 | 3,390 | ||||||
|
Inventories
|
6,304 | 6,148 | ||||||
|
Prepaid expenses and other
|
351 | 326 | ||||||
|
Total current assets
|
10,828 | 11,673 | ||||||
|
Property and equipment, net
|
492 | 474 | ||||||
|
Other assets
|
95 | 78 | ||||||
|
Total assets
|
$ | 11,415 | $ | 12,225 | ||||
|
LIABILITIES AND SHAREHOLDERS' EQUITY
|
||||||||
|
Current liabilities:
|
||||||||
|
Line of credit
|
$ | 1,000 | $ | 777 | ||||
|
Accounts payable
|
1,586 | 1,892 | ||||||
|
Accrued expenses
|
1,435 | 1,390 | ||||||
|
Customer deposits and deferred revenue, short-term
|
761 | 1,058 | ||||||
|
Total current liabilities
|
4,782 | 5,117 | ||||||
|
Income taxes payable
|
8 | 71 | ||||||
|
Deferred rent, net of current portion
|
-- | 8 | ||||||
|
Total liabilities
|
4,790 | 5,196 | ||||||
|
Aehr Test Systems shareholders' equity:
|
||||||||
|
Common stock, $0.01 par value:
Authorized: 75,000;
|
||||||||
|
Issued and outstanding: 11,498 shares and
|
||||||||
|
11,203 shares at August 31, 2014 and
|
||||||||
|
May 31, 2014, respectively
|
115 | 112 | ||||||
|
Additional paid-in capital
|
52,678 | 52,142 | ||||||
|
Accumulated other comprehensive income
|
2,451 | 2,488 | ||||||
|
Accumulated deficit
|
(48,599 | ) | (47,692 | ) | ||||
|
Total Aehr Test Systems shareholders' equity
|
6,645 | 7,050 | ||||||
|
Noncontrolling interest
|
(20 | ) | (21 | ) | ||||
|
Total shareholders' equity
|
6,625 | 7,029 | ||||||
|
Total liabilities and shareholders' equity
|
$ | 11,415 | $ | 12,225 | ||||
|
Three Months Ended
|
||||||||
|
August 31,
|
||||||||
|
2014
|
2013
|
|||||||
|
Net sales
|
$ | 3,558 | $ | 3,752 | ||||
|
Cost of sales
|
1,948 | 1,808 | ||||||
|
Gross profit
|
1,610 | 1,944 | ||||||
|
Operating expenses:
|
||||||||
|
Selling, general and administrative
|
1,624 | 1,420 | ||||||
|
Research and development
|
959 | 681 | ||||||
|
Total operating expenses
|
2,583 | 2,101 | ||||||
|
Loss from operations
|
(973 | ) | (157 | ) | ||||
|
Interest expense
|
(14 | ) | (4 | ) | ||||
|
Other income (expense), net
|
31 | (34 | ) | |||||
|
Loss before income tax benefit
|
(956 | ) | (195 | ) | ||||
|
Income tax benefit
|
49 | 29 | ||||||
|
Net loss
|
(907 | ) | (166 | ) | ||||
|
Less: Net income attributable to
the noncontrolling interest
|
-- | -- | ||||||
|
Net loss attributable to Aehr
Test Systems common shareholders
|
$ | (907 | ) | $ | (166 | ) | ||
|
Net loss per share – Basic and diluted
|
$ | (0.08 | ) | $ | (0.02 | ) | ||
|
Shares used in per share calculations:
|
||||||||
|
Basic and diluted
|
11,391 | 10,635 | ||||||
|
Three Months Ended
|
||||||||
|
August 31,
|
||||||||
|
2014
|
2013
|
|||||||
|
Net loss
|
$ | (907 | ) | $ | (166 | ) | ||
| Other comprehensive (loss) income, net of tax: | ||||||||
|
Net change in cumulative translation
adjustments
|
(36 | ) | 22 | |||||
|
Total comprehensive loss
|
(943 | ) | (144 | ) | ||||
|
Less: Comprehensive income (loss)
attributable to the noncontrolling interest
|
1 | (1 | ) | |||||
|
Comprehensive loss, attributable to
Aehr Test Systems
|
$ | (944 | ) | $ | (143 | ) | ||
|
Three Months Ended
|
||||||||
|
August 31,
|
||||||||
|
2014
|
2013
|
|||||||
|
Cash flows from operating activities:
|
||||||||
|
Net loss
|
$ | (907 | ) | $ | (166 | ) | ||
|
Adjustments to reconcile net loss to
net cash (used in) provided by operating
activities:
|
||||||||
|
Stock-based compensation expense
|
197 | 143 | ||||||
|
(Recovery of) provision for doubtful accounts
|
(20 | ) | 7 | |||||
|
Loss on disposal of assets
|
-- | 9 | ||||||
|
Depreciation and amortization
|
29 | 53 | ||||||
|
Changes in operating assets and liabilities:
|
||||||||
|
Accounts receivable
|
1,272 | (216 | ) | |||||
|
Inventories
|
(156 | ) | -- | |||||
|
Prepaid expenses and other
|
(46 | ) | (181 | ) | ||||
|
Accounts payable
|
(270 | ) | 175 | |||||
|
Accrued expenses
|
38 | 7 | ||||||
|
Customer deposits and deferred revenue
|
(294 | ) | 409 | |||||
|
Income taxes payable
|
(53 | ) | (45 | ) | ||||
|
Deferred rent
|
(8 | ) | (23 | ) | ||||
|
Net cash (used in) provided by
operating activities
|
(218 | ) | 172 | |||||
|
Cash flows from investing activities:
|
||||||||
|
Purchases of property and equipment
|
(21 | ) | (6 | ) | ||||
|
Net cash used in
investing activities
|
(21 | ) | (6 | ) | ||||
|
Cash flows from financing activities:
|
||||||||
|
Line of credit borrowings (repayments), net
|
223 | (154 | ) | |||||
|
Proceeds from issuance of common stock
and exercise of stock options
|
315 | 59 | ||||||
|
Net cash provided by (used in)
financing activities
|
538 | (95 | ) | |||||
|
Effect of exchange rates on cash
|
(33 | ) | 40 | |||||
|
Net increase in cash and
cash equivalents
|
266 | 111 | ||||||
|
Cash and cash equivalents, beginning of period
|
1,809 | 2,324 | ||||||
|
Cash and cash equivalents, end of period
|
$ | 2,075 | $ | 2,435 | ||||
|
Three Months Ended
|
||||||||
|
August 31,
|
||||||||
|
2014
|
2013
|
|||||||
|
Stock-based compensation in the form of employee
stock options and ESPP shares, included in:
|
||||||||
|
Cost of sales
|
$ | 14 | $ | 8 | ||||
|
Selling, general and administrative
|
148 | 104 | ||||||
|
Research and development
|
35 | 31 | ||||||
|
Total stock-based compensation
|
$ | 197 | $ | 143 | ||||
|
Three Months Ended
|
||||||||
|
August 31,
|
||||||||
|
2014
|
2013
|
|||||||
|
Expected term (in years)
|
4 | 4 | ||||||
|
Volatility
|
0.91 | 0.95 | ||||||
|
Expected dividend
|
$ | 0.00 | $ | 0.00 | ||||
|
Risk-free interest rates
|
1.28 | % | 1.46 | % | ||||
|
Estimated forfeiture rate
|
0.25 | % | 0.25 | % | ||||
|
Weighted average grant date fair value
|
$ | 1.71 | $ | 0.92 | ||||
|
Outstanding Options
|
||||||||||||||||
|
Weighted
|
||||||||||||||||
|
Number
|
Average
|
Aggregate
|
||||||||||||||
|
Available
|
of
|
Exercise
|
Intrinsic
|
|||||||||||||
|
Shares
|
Shares
|
Price
|
Value
|
|||||||||||||
|
Balances, May 31, 2014
|
1,145 | 3,002 | $ | 1.31 | $ | 2,913 | ||||||||||
|
Options granted
|
(625 | ) | 625 | $ | 2.65 | |||||||||||
|
Options terminated
|
9 | (9 | ) | $ | 1.27 | |||||||||||
|
Options exercised
|
-- | (295 | ) | $ | 1.07 | |||||||||||
|
Balances, August 31, 2014
|
529 | 3,323 | $ | 1.59 | $ | 3,277 | ||||||||||
|
Options fully vested and expected to
vest at August 31, 2014
|
3,257 | $ | 1.59 | $ | 3,212 | |||||||||||
|
Options exercisable at August 31, 2014
|
1,768 | $ | 1.26 | $ | 2,074 | |||||||||||
|
Options Outstanding
|
Options Exercisable
|
|||||||||||||||||||||||||
|
at August 31, 2014
|
at August 31, 2014
|
|||||||||||||||||||||||||
|
Range of Exercise
Prices
|
Number Outstanding Shares
|
Weighted Average Remaining Contractual Life (Years)
|
Weighted Average Exercise Price
|
Number Exercisable Shares
|
Weighted Average Remaining Contractual Life (Years)
|
Weighted Average Exercise Price
|
Aggregate Intrinsic Value
|
|||||||||||||||||||
| $0.59-$0.97 | 680 | 4.59 | $ | 0.70 | 536 | 4.66 | $ | 0.73 | ||||||||||||||||||
| $1.09-$1.42 | 1,351 | 4.67 | $ | 1.28 | 675 | 4.15 | $ | 1.28 | ||||||||||||||||||
| $1.73-$1.95 | 428 | 2.68 | $ | 1.88 | 365 | 2.11 | $ | 1.90 | ||||||||||||||||||
| $2.15-$2.71 | 864 | 6.07 | $ | 2.63 | 192 | 4.73 | $ | 1.47 | ||||||||||||||||||
| $0.59-$2.71 | 3,323 | 4.76 | $ | 1.59 | 1,768 | 3.94 | $ | 1.26 |
$2,074
|
|||||||||||||||||
|
Three Months Ended
|
||||||||
|
August 31,
|
||||||||
|
2014
|
2013
|
|||||||
|
Numerator: Net loss
|
$ | (907 | ) | $ | (166 | ) | ||
|
Denominator for basic net loss
per share:
|
||||||||
|
Weighted-average shares outstanding
|
11,391 | 10,635 | ||||||
|
Shares used in basic net loss
per share calculation
|
11,391 | 10,635 | ||||||
|
Effect of dilutive securities
|
-- | -- | ||||||
|
Denominator for diluted net loss
per share
|
11,391 | 10,635 | ||||||
|
Basic net loss per share
|
$ | (0.08 | ) | $ | (0.02 | ) | ||
|
Diluted net loss per share
|
$ | (0.08 | ) | $ | (0.02 | ) | ||
|
Balance as of
|
||||||||||||||||
|
August 31,
2014
|
Level 1
|
Level 2
|
Level 3
|
|||||||||||||
|
Money market funds
|
$ | 527 | $ | 527 | $ | -- | $ | -- | ||||||||
|
Certificate of deposit
|
50 | -- | 50 | -- | ||||||||||||
|
Assets
|
$ | 577 | $ | 527 | $ | 50 | $ | -- | ||||||||
|
Liabilities
|
$ | -- | $ | -- | $ | -- | $ | -- | ||||||||
|
Balance as of
|
||||||||||||||||
|
May 31,
2014
|
Level 1
|
Level 2
|
Level 3
|
|||||||||||||
|
Money market funds
|
$ | 477 | $ | 477 | $ | -- | $ | -- | ||||||||
|
Certificate of deposit
|
50 | -- | 50 | -- | ||||||||||||
|
Assets
|
$ | 527 | $ | 477 | $ | 50 | $ | -- | ||||||||
|
Liabilities
|
$ | -- | $ | -- | $ | -- | $ | -- | ||||||||
|
August 31,
|
May 31,
|
|||||||
|
2014
|
2014
|
|||||||
|
Raw materials and sub-assemblies
|
$ | 3,504 | $ | 3,348 | ||||
|
Work in process
|
2,558 | 2,585 | ||||||
|
Finished goods
|
242 | 215 | ||||||
| $ | 6,304 | $ | 6,148 | |||||
|
United
|
||||||||||||||||
|
States
|
Asia
|
Europe
|
Total
|
|||||||||||||
|
Three months ended August 31, 2014:
|
||||||||||||||||
|
Net sales
|
$ | 1,663 | $ | 1,086 | $ | 809 | $ | 3,558 | ||||||||
|
Property and equipment, net
|
435 | 40 | 17 | 492 | ||||||||||||
|
Three months ended August 31, 2013:
|
||||||||||||||||
|
Net sales
|
$ | 1,338 | $ | 2,316 | $ | 98 | $ | 3,752 | ||||||||
|
Property and equipment, net
|
202 | 44 | -- | 246 | ||||||||||||
|
Three Months Ended
|
||||||||
|
August 31,
|
||||||||
|
2014
|
2013
|
|||||||
|
Balance at the beginning of the period
|
$ | 223 | $ | 222 | ||||
|
Accruals for warranties issued
during the period
|
32 | 92 | ||||||
|
Settlement made during the period
(in cash or in kind)
|
(87 | ) | (88 | ) | ||||
|
Balance at the end of the period
|
$ | 168 | $ | 226 | ||||
|
August 31,
|
May 31,
|
|||||||
|
2014
|
2014
|
|||||||
|
Customer deposits
|
$ | 636 | $ | 871 | ||||
|
Deferred revenue, short-term
|
125 | 187 | ||||||
| $ | 761 | $ | 1,058 | |||||
|
Three Months Ended
|
||||||||
|
August 31,
|
||||||||
|
2014
|
2013
|
|||||||
|
Net sales
|
100.0 | % | 100.0 | % | ||||
|
Cost of sales
|
54.7 | 48.2 | ||||||
|
Gross profit
|
45.3 | 51.8 | ||||||
|
Operating expenses:
|
||||||||
|
Selling, general and administrative
|
45.6 | 37.8 | ||||||
|
Research and development
|
27.0 | 18.2 | ||||||
|
Total operating expenses
|
72.6 | 56.0 | ||||||
|
Loss from operations
|
(27.3 | ) | (4.2 | ) | ||||
|
Interest expense
|
(0.4 | ) | (0.1 | ) | ||||
|
Other income (expense), net
|
0.9 | (0.9 | ) | |||||
|
Loss before income tax benefit
|
(26.8 | ) | (5.2 | ) | ||||
|
Income tax benefit
|
1.3 | 0.8 | ||||||
|
Net loss
|
(25.5 | ) | (4.4 | ) | ||||
|
Less: Net income attributable
to the noncontrolling interest
|
-- | -- | ||||||
|
Net loss attributable to Aehr
Test Systems common shareholders
|
(25.5 | )% | (4.4 | )% | ||||
|
Aehr Test Systems
|
|||
|
(Registrant)
|
|||
|
Date: October 14, 2014
|
By:
|
/s/ GAYN ERICKSON | |
|
Gayn Erickson
|
|||
|
President and Chief Executive
Officer
|
|||
|
Date: October 14, 2014
|
/s/ GARY L. LARSON
|
||
|
Gary L. Larson
|
|||
|
Vice President of Finance and
Chief Financial Officer
|
|||
| Exhibit No. | Description | |
| 10.1(1) |
Fourth Amendment to Loan and Security Agreement dated August 22,
2014 by and between Aehr Test Systems and Silicon Valley Bank.
|
|
|
|
||
| 10.2(1) |
Fourth Amendment to Export-Import Bank Loan and Security Agreement
dated August 22, 2014 by and between Aehr Test Systems and Silicon
Valley Bank.
|
|
| 31.1 |
Certification of Chief Executive Officer pursuant to Rules
13a-14(a) and 15d-14(a) promulgated under the Securities
Exchange Act of 1934, as amended, as adopted pursuant to
Section 302(a) of the Sarbanes-Oxley Act of 2002.
|
|
| 31.2 |
Certification of Chief Financial Officer pursuant to Rules
13a-14(a) and 15d-14(a) promulgated under the Securities
Exchange Act of 1934, as amended, as adopted pursuant to
Section 302(a) of the Sarbanes-Oxley Act of 2002.
|
|
| 32.1 |
Certification of Chief Executive Officer and Chief Financial
Officer pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
|
|
| 101.INS |
XBRL Instance Document
|
|
| 101.SCH |
XBRL Taxonomy Extension Schema Document
|
|
| 101.CAL |
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
| 101.DEF |
XBRL Taxonomy Extension Definition Linkbase Document
|
|
| 101.LAB |
XBRL Taxonomy Extension Label Linkbase Document
|
|
| 101.PRE |
XBRL Taxonomy Extension Presentation Linkbase Document
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|